Ipamorelin + CJC-1295 GH Optimization Stack
A research protocol for combined Ipamorelin + CJC-1295 GH-axis stimulation, based on published GHSR-1a and GHRH-receptor research. The stack activates both GH-release pathways simultaneously for synergistic GH pulse amplification.
Dosing
Published research on GHSR-1a agonists (Ipamorelin) and GHRH analogs (CJC-1295 / Mod-GRF) uses doses calibrated to produce physiological (not supraphysiological) GH stimulation. Ipamorelin research has used 200–300 µg per injection in animal models; CJC-1295 (no DAC) in the Jette et al. clinical study used 30–60 µg/kg with dose-dependent GH responses documented.
All figures are drawn from published research and do not constitute dosing recommendations for human use.
Cycle structure
Published research on GH secretagogue stacks uses administration timing designed to coincide with the physiological GH pulse window: typically pre-sleep (when pituitary somatotrophs are most responsive to GHRH and ghrelin stimulation). Research protocols run for 12–16 weeks to allow downstream IGF-1 and body composition changes to become measurable. Ipamorelin and CJC-1295 are typically co-administered simultaneously to maximise dual-receptor synergy.
Bloodwork
Researchers monitoring GH secretagogue stacks have measured: GH pulse amplitude and frequency (frequent blood sampling, GH ELISA); IGF-1 (serum ELISA, measured at 4, 8, 12 weeks); body composition (DXA scan for lean mass and fat mass); fasting glucose and insulin (secondary endpoints for metabolic effects); and GH-related markers (IGFBP-3, ALS). In aging research specifically: bone mineral density (DXA), sleep quality (polysomnography), and lipid panel.
Risk & contraindications
Both Ipamorelin and CJC-1295 (no DAC) have demonstrated favourable safety profiles in published research. Ipamorelin''s selective GHSR-1a agonism minimises cortisol and ACTH elevation — the primary safety concern with first-generation GHRPs. CJC-1295 (no DAC) produces physiological-range GH elevation. Water retention and transient glucose elevation are potential secondary effects of GH elevation generally. No significant adverse events are reported in published Ipamorelin studies.
Protocol Overview
This protocol outlines research parameters for combined Ipamorelin + CJC-1295 growth hormone axis investigations.
Research goal: Longevity — GH axis restoration, body composition, IGF-1 Primary peptides: Ipamorelin (GHSR-1a agonist) + CJC-1295 no DAC (GHRHR agonist) Duration: 12 weeks Model systems: Rodent GH-deficient models, healthy young and aged adult studies (Jette et al.)
Scientific Rationale for the Stack
The pituitary somatotroph has two primary positive receptors for GH release: the GHRH receptor (GHRHR) and the ghrelin receptor (GHSR-1a). Ipamorelin activates GHSR-1a; CJC-1295 activates GHRHR. Simultaneous activation of both receptors produces synergistic GH release — a greater amplitude GH pulse than either peptide alone. This dual-receptor mechanism is documented in in vitro somatotroph studies and forms the pharmacological basis for the stack's use in GH-axis aging research.
The no-DAC form of CJC-1295 is used in this protocol (not the 8-day DAC form) to maintain pulsatile GH release — the physiologically normal pattern — rather than continuous GH elevation.
Referenced Research
Research Use Only · Not for human consumption · Consult a qualified researcher or physician before any protocol.
Compounds in this protocol